BioWorld-Insight-2010-08-09

"Change of control." It's one of those legal phrases in a contract that, when brought into play, can strike terror or joy into the heart of one side of a partnership or another who might have more casually agreed years earlier. The concept could take center stage for BioMarin Pharmaceutical Inc. in the firm's deal with Genzyme Corp. if Sanofi-Aventis SA goes ahead with a persistent bid to take over Cambridge, Mass.-based Genzyme Corp. – a bid that speculators predicted could turn hostile.